Released Mar 30, 2023, after the close
10-K filed Mar 30, 2023, 89 days after period end · 0000950170-23-010976
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$8.63M$8.63M derived−19.0% vs Q4 2021−65.7% vs Q3 2022
Net Income-$34.59M-$34.59M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$49,222,000N/M
Operating Cash Flowderived-$23,864,000N/M
Margins · derived
Operating margin-570.2%−241.4 pt vs Q4 2021
Net margin-400.8%−42.9 pt vs Q4 2021
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $8.63M | $10.65M | $8.28M | $11.31M |
| Net Income | -$34.59M | -$38.13M | -$59.54M | -$14.79M |
| EPS Diluted | — | — | -$1.48 | -$0.65 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR